Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSH01-TCRT in Solid Tumors
NCT05580796Phase 1Recruiting
- Sponsor
- TScan Therapeutics, Inc.
- Start
- Oct 2022
- Primary completion
- Oct 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSH01-TCR-T in solid tumor, sponsored by TScan Therapeutics, Inc. Primary endpoints: Number of participants with treatment-related adverse events at 3 years and Objective Response Rate at 3 years. Started Oct 2022; status: recruiting.
02
Drugs
KSH01-TCR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05580796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580796.